Patents Issued in August 15, 2019
-
Publication number: 20190248846Abstract: Disclosed are novel fusion protein constructs comprising a functional mitochondrial protein, that can enter mitochondria within intact cells. Further disclosed are methods of treating mitochondrial disorders by the disclosed fusion proteins and compositions therefor.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Inventors: Haya Lorberboum-Galski, Hagar Greif
-
Publication number: 20190248847Abstract: A recombinant spider silk protein, consisting of no more than 800 amino acids, comprising a set of domains arranged according to the formula (NT)-REP-CT, wherein: the optional NT-domain, if present, comprises a sequence of 100 to 160 amino-acid residues derived from the N-terminal domain of a spider silk protein; the REP-domain comprises a sequence of 30 to 600 amino acid residues derived from the repetitive segment of a spider silk protein; and the CT-domain comprises a sequence of 70 to 120 amino acid residues derived from the C-terminal domain of a spider silk protein selected from: a sequence of 72 to 110 amino acid residues derived from the C-terminal domain of a spider silk protein, wherein the sequence comprises at least 7 residues independently selected from K, R, E and D; a sequence having at least 85% identity to SEQ ID NO: 15 or any one of SEQ ID NO:s 62-65 or 67-73; and a sequence having at least 70% identity to SEQ.Type: ApplicationFiled: June 29, 2017Publication date: August 15, 2019Applicant: SPIBER TECHNOLOGIES ABInventors: Anna Rising, Jan Johansson, Marlene Andersson
-
Publication number: 20190248848Abstract: Compositions and methods relating to synthetic modification of histone-binding proteins. Some histone-binding fusion-protein compositions include a modified polycomb chromodomain (PCD) motif, for example two tandem copies of the H3K27me3-binding PCD at the N-terminus separated by a linker. Some methods relate to multivalent engagement of one or more histone proteins or to tuning the activity of a synthetic histone-binding transcriptional regulator, for example by contacting the one or more histone proteins with a histone-binding fusion-protein composition having a modified PCD motif.Type: ApplicationFiled: February 13, 2019Publication date: August 15, 2019Inventors: Karmella Haynes, Stefan Tekel
-
Publication number: 20190248849Abstract: The present invention is related to development of the improved cell-permeable (CP)-?SOCS3 recombinant protein which disrupt the interaction of leptin receptor (ObR) and suppressor of cytokine signaling 3 (SOCS3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.Type: ApplicationFiled: April 12, 2019Publication date: August 15, 2019Inventor: Daewoong JO
-
Publication number: 20190248850Abstract: The disclosure provides systems and methods useful for predicting or detecting a malfunction in a chromatography process in real-time. In some embodiments, the disclosure provides systems and methods for detecting an atypical profile in a process chromatogram in ion-exchange chromatography of a biologic product.Type: ApplicationFiled: February 14, 2019Publication date: August 15, 2019Inventors: Nathan L. MAO, Scott CARVER, Bernhard SCHILLING, Eric SHIERLY
-
Publication number: 20190248851Abstract: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.Type: ApplicationFiled: February 22, 2019Publication date: August 15, 2019Inventors: Kang TING, Chia SOO
-
Publication number: 20190248852Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. 5 The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.Type: ApplicationFiled: May 24, 2017Publication date: August 15, 2019Applicants: Novo Nordisk A/S, Novo Nordisk A/SInventors: Xujia Zhang, Xiang Gao, Hongtao Guan, Henning Thoegersen, Kristian Sass-Oerum, Lars Fogh Iversen, Per Noergaard, Sebastian Beck Joergensen, Kristian Tage Hansen, Yi Wang
-
Publication number: 20190248853Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Inventors: Lloyd A. Greene, James Angelastro
-
Publication number: 20190248854Abstract: Methods for modifying a dystrophin gene are disclosed, for restoring dystrophin expression within a cell having an endogenous frameshift or nonsense mutation within the dystrophin gene. The methods comprise introducing a first cut within an exon en or intron of the dystrophin gene creating a first exon end or intron end, wherein said first cut is located upstream of the endogenous frameshift or nonsense mutation; and introducing a second cut within an exon or intron of the dystrophin gene creating a second exon end or intron end, wherein said second cut is located downstream of the frameshift or nonsense mutation. Upon joining/ligation of said first and second exon ends or intron ends a hybrid exon or intron junction is created and dystrophin expression is restored, as the correct reading frame is restored. Reagents and uses of the method are also disclosed, for example to treat a subject suffering from muscular dystrophy.Type: ApplicationFiled: September 21, 2017Publication date: August 15, 2019Inventors: JACQUES P. TREMBLAY, JEAN-PAUL IYOMBE-ENGEMBE, PIERRE CHAPDELAINE, DANIEL AGUDELO, BENJAMIN DUCHÊNE
-
Publication number: 20190248855Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, 5495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, 51255L, K1334G, 51359A, E1371Q, H14025, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.Type: ApplicationFiled: February 15, 2019Publication date: August 15, 2019Inventors: John C. Kappes, Zhengrong Yang, Christie G. Brouillette, Ina L. Urbatsch
-
Publication number: 20190248856Abstract: Provided are Listeria-based immunogenic compositions comprising Wilms tumor protein (WT1) antigens and methods for treating and vaccinating against cancer and inducing an immune response against the same in a subject. Also provided herein are recombinant fusion polypeptides or chimeric polypeptides comprising Wilms tumor protein antigens, nucleic acids encoding such chimeric polypeptides or fusion polypeptides, recombinant bacteria or Listeria strains comprising such chimeric polypeptides or fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such chimeric polypeptides or fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such chimeric polypeptides or fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains.Type: ApplicationFiled: June 30, 2017Publication date: August 15, 2019Applicant: Advaxis, Inc.Inventors: Michael Princiotta, Robert Petit
-
Publication number: 20190248857Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: April 17, 2019Publication date: August 15, 2019Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
-
Publication number: 20190248858Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Applicant: AskGene Pharma Inc.Inventors: Jian-Feng Lu, Yuefeng Lu, Aijun Wang, Donggou He, Kurt Shanebeck, Chen Yao
-
Publication number: 20190248859Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.Type: ApplicationFiled: August 24, 2017Publication date: August 15, 2019Applicant: BRIM Biotechnology, Inc.Inventors: Frank Wen-Chi Lee, Kuanyin Karen Lin, Yeou-Ping Tsao, Tsung-Chuan Ho
-
Publication number: 20190248860Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.Type: ApplicationFiled: December 13, 2018Publication date: August 15, 2019Inventors: Kenan Christopher Garcia, Aron Levin, Aaron Ring
-
Publication number: 20190248861Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.Type: ApplicationFiled: October 24, 2018Publication date: August 15, 2019Applicant: Ipsen Pharma S.A.S.Inventors: Rakesh Datta, Zheng Xin Dong
-
Publication number: 20190248862Abstract: A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an FSH? sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (FSH) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to NKG2D. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified T cells expressing the chimeric protein, as well as method of using these compositions for the treatment of FSHR-expressing cancers or tumor cells are also provided.Type: ApplicationFiled: February 21, 2019Publication date: August 15, 2019Inventors: Alfredo Perales-Puchalt, Jose R. Conejo-Garcia
-
Publication number: 20190248863Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.Type: ApplicationFiled: February 26, 2019Publication date: August 15, 2019Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIIVAN
-
Publication number: 20190248864Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Inventors: Jeff Lynn ELLSWORTH, Joseph Beene BOLEN, Francine Marie GREGOIRE, Justin GUILD
-
Publication number: 20190248865Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.Type: ApplicationFiled: October 21, 2016Publication date: August 15, 2019Inventors: Jingwei LU, Zhiyuan YANG, Cheng LIU, Hong LIU, Yiyang XU, Su YAN, Vivien Wai-Fan CHAN, Lucas HORAN
-
Publication number: 20190248866Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.Type: ApplicationFiled: April 30, 2018Publication date: August 15, 2019Inventors: Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
-
Publication number: 20190248867Abstract: Compositions for the treatment or prevention of multiple sclerosis are provided. In some embodiments, the composition comprises an isolated peptide comprising a partial amino acid sequence of a myelin oligodendrocyte glycoprotein (MOG) protein, wherein the peptide activates regulatory T cells. In some embodiments, the composition comprises dendritic cells pulsed with a MOG peptide that activates regulatory T cells. In some embodiments, the peptide activates HLA-E-restricted regulatory CD8+ T cells.Type: ApplicationFiled: June 30, 2017Publication date: August 15, 2019Inventors: Xiaolei TANG, David J. BAYLINK
-
Publication number: 20190248868Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: April 12, 2019Publication date: August 15, 2019Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Publication number: 20190248869Abstract: A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (i CAR) capable of preventing or attenuating undesired activation of an effector immune cell, wherein the i CAR comprises an extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope absent from mammalian tumor cells due to loss of heterozygosity (LOH) but present at least on all cells of related mammalian normal tissue; and an intracellular domain comprising at least one signal transduction element that inhibits an effector immune cell is provided. Vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.Type: ApplicationFiled: September 28, 2017Publication date: August 15, 2019Inventors: Gideon Gross, Merav Beiman, William Gibson
-
Publication number: 20190248870Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?7 binding.Type: ApplicationFiled: February 22, 2019Publication date: August 15, 2019Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
-
Publication number: 20190248871Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.Type: ApplicationFiled: October 26, 2017Publication date: August 15, 2019Inventors: Joon Won LEE, Won Yong HAN, Su Jung KIM, Jun Seok OH, So Young KIM, Kwang Woo KIM, Yeon Kyeong SHIN
-
Publication number: 20190248872Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.Type: ApplicationFiled: January 22, 2019Publication date: August 15, 2019Inventors: Ray Camphausen, Amna Saeed-Kothe, Jonathan Davis, Tracy S. Mitchell
-
Publication number: 20190248873Abstract: Some embodiments of the systems, methods and compositions provided herein relate to a compound protease. In some embodiments, the compound protease includes a protease domain and a cut site for another enzyme. In some embodiments, the compound protease includes an association domain. In some embodiments, the compound protease is part of a protein circuit.Type: ApplicationFiled: January 17, 2019Publication date: August 15, 2019Inventors: Xiaojing Gao, Lucy S. Chong, Michael Elowitz, Mark William Budde, Matthew Sun-min Kim
-
Publication number: 20190248874Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: ApplicationFiled: November 1, 2018Publication date: August 15, 2019Inventor: Antonio Lanzavecchia
-
Publication number: 20190248875Abstract: Provided herein are a mutant envelope protein of Zika virus and a nucleic acid molecule including a nucleotide sequence encoding the mutant envelope protein. The mutant envelope protein, which preferably has a threonine substitution at 105th position, or an asparagine substitution at 248th position and a threonine substitution at 250th position in an amino acid sequence of SEQ ID NO: 1, includes an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus. Also provided herein is a vaccine composition, including the mutant envelope protein or a recombinant virus including the nucleic acid molecule. Also provided herein is a method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, including administering to a subject in need thereof an effective amount of a vaccine composition including the mutant envelope protein of Zika virus.Type: ApplicationFiled: July 17, 2018Publication date: August 15, 2019Inventors: Suh-Chin Wu, Shao-Ping Yang, Hsiao-Han Lin
-
Publication number: 20190248876Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Inventors: Victor J. TORRES, Tamara REYES-ROBLES, Francis ALONZO, III
-
Publication number: 20190248877Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one antigen binding moiety capable of specific binding to Tenascin-C (TnC) and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecules are characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or two fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof. The invention further relates to methods of producing these molecules and to methods of using the same.Type: ApplicationFiled: November 9, 2018Publication date: August 15, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
-
Publication number: 20190248878Abstract: The present invention provides: an antibody which specifically bonds to human NINJ-1; and a fragment thereof. The antibody or the fragment thereof according to the present invention has very high bonding affinity and bonding specificity with respect to a human NINJ-1 or a homogeneous binding site of the protein, and does not exhibit cross-reactivity with NINJ-1 proteins that are derived from other organisms and have high protein similarity. Accordingly, the present invention provides significant advantages with respect to accuracy and sensitivity and the like, not only in diagnosing disease related to NINJ-1 proteins but also in inhibiting pathological conditions involving NINJ-1 proteins. In particular, the antibody provided according to the present invention has a remarkable effect of inhibiting attachment between immunocytes and human cerebral endothelial cells, and thus has an effect of treating multiple sclerosis.Type: ApplicationFiled: August 28, 2017Publication date: August 15, 2019Inventors: Young Kee SHIN, Seahyung LEE, Kyoung SONG, Ji Hye LEE
-
Publication number: 20190248879Abstract: The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using said mutant p53 polypeptide as an immunogen wherein said polypeptide comprises: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration, in particular wherein the scaffold sequence is thioredoxin. In the specific embodiments, antibodies against mutant p53 comprising R175H, R248Q or R273H are generated. Also disclosed are the uses of said antibodies for diagnosis, prognosis and stratification of patient groups and further encompasses the use of antibodies for imaging and treatment of cancer.Type: ApplicationFiled: October 17, 2017Publication date: August 15, 2019Inventors: Tr Kanaga Sabapathy, David P. Lane, Le-Ann Hwang, Xin Yu Koh, Liew Oi Wah
-
Publication number: 20190248880Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.Type: ApplicationFiled: April 22, 2019Publication date: August 15, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
-
Publication number: 20190248881Abstract: The present invention provides TGF-? antagonists and conjugates thereof, as well as methods of using such compositions for attenuating TGF-? signaling. These novel compositions and methods may be useful for treating individuals suffering from devastating diseases associated with elevated TGF-? signaling, including skeletal disorders, such as osteogenesis imperfecta (OI), and muscular diseases, such as muscular dystrophies.Type: ApplicationFiled: December 4, 2018Publication date: August 15, 2019Inventors: Philippe CRINE, Susan SCHIAVI
-
Publication number: 20190248882Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.Type: ApplicationFiled: April 16, 2019Publication date: August 15, 2019Inventors: Yanbin Liang, Daniel W. Gil
-
Publication number: 20190248883Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: February 20, 2019Publication date: August 15, 2019Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, D.M.Sc., Debra HUDSON, Jørgen PETERSEN
-
Publication number: 20190248884Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.Type: ApplicationFiled: February 25, 2019Publication date: August 15, 2019Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
-
Publication number: 20190248885Abstract: Provided are methods of modulating neuronal and/or oligodendrocyte survival. The subject methods relate to preventing neuronal and/or oligodendrocyte death or increasing neuron or oligodendrocyte death. Also provided are neuroprotective compositions and neurotoxic compositions. Methods of identifying neurotoxins, methods of identifying neurotoxin inhibitors and methods of identifying neurotoxin conditions in a subject are also provided.Type: ApplicationFiled: October 25, 2017Publication date: August 15, 2019Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Shane Antony Liddelow, Kevin Guttenplan, Ben A. Barres
-
Publication number: 20190248886Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.Type: ApplicationFiled: April 26, 2019Publication date: August 15, 2019Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
-
Publication number: 20190248887Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.Type: ApplicationFiled: November 15, 2018Publication date: August 15, 2019Inventors: James R. Prudent, Jon S. Thorson
-
Publication number: 20190248888Abstract: The present invention provides glucagon signaling pathway antagonists for use in combination with amino acid transport inhibitors, or mTOR inhibitors for lowering blood glucose levels in patients suffering from a disease or condition characterized in part by elevated blood glucose levels. According to certain embodiments of the invention, the glucagon signaling pathway antagonists are fully human antibodies that bind to human GCG or human GCGR. The antibodies of the invention, when combined with either SLC38A5 inhibitors or with an mTOR inhibitor are useful for lowering blood glucose levels, without resulting in alpha cell hyperplasia, and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.Type: ApplicationFiled: October 19, 2017Publication date: August 15, 2019Inventors: Jinrang Kim, Haruka Okamoto, Andrew J. Murphy, Jesper Gromada, George D. Yancopoulos
-
Publication number: 20190248889Abstract: The invention provides anti-LgR5 antibodies and methods of using the same.Type: ApplicationFiled: April 22, 2019Publication date: August 15, 2019Applicant: GENENTECH, INC.Inventors: Andrew G. Polson, Weiguang Mao, Ron Firestein
-
Publication number: 20190248890Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.Type: ApplicationFiled: February 8, 2019Publication date: August 15, 2019Applicant: UCB Biopharma SPRLInventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
-
Publication number: 20190248891Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.Type: ApplicationFiled: February 27, 2019Publication date: August 15, 2019Inventor: Michael C. Jensen
-
Publication number: 20190248892Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: ApplicationFiled: February 28, 2019Publication date: August 15, 2019Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20190248893Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.Type: ApplicationFiled: July 13, 2017Publication date: August 15, 2019Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Y. HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
-
Publication number: 20190248894Abstract: This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.Type: ApplicationFiled: July 20, 2017Publication date: August 15, 2019Applicants: Fred Hutchinson Cancer Research Center, The Board of Trustees of The Leland Stanford Junior UniversityInventors: Irwin Bernstein, Vincent Luca, Kenan Christopher Garcia
-
Publication number: 20190248895Abstract: This disclosure relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.Type: ApplicationFiled: October 19, 2017Publication date: August 15, 2019Inventors: CARINE PATUREL, HELENE SICARD